CD38 and plasma cell myeloma: Isatuximab (Sarclisa®) is an immunoglobulin (Ig)G1 monoclonal antibody (mAb) that targets a specific epitope of CD38 and contributes to myeloma cell killing via multiple mechanisms of action.8, 9, 10